XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Numerator:        
Net loss $ (8,540) $ (5,468) $ (21,525) $ (18,983)
Less: Net loss attributable to noncontrolling interests (1,886) (1,207) (4,753) (4,564)
Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted (6,654) (4,261) (16,772) (14,419)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic $ (6,654) $ (4,261) $ (16,772) $ (14,419)
Class A Common Stock        
Denominator:        
Weighted-average number of vTv Therapeutics Inc. Class A common stock, basic (in shares) 81,483,600 80,490,121 81,483,600 72,649,531
Weighted-average number of vTv Therapeutics Inc. Class A common stock, diluted (in shares) 81,483,600 80,490,121 81,483,600 72,649,531
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic (in usd per share) $ (0.08) $ (0.05) $ (0.21) $ (0.20)
Net loss per share of vTv Therapeutics Inc. Class A common stock, diluted (in usd per share) $ (0.08) $ (0.05) $ (0.21) $ (0.20)